🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06577519
Recruiting Phase 3

Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

NCT06577519 · tracked via the Priya Life Science China tracker
Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Phase
Phase 3
Started
2024-09-06
Last updated
2026-07-27

Condition(s) studied

Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Investigational drug(s) / intervention(s)

VicagrelClopidogrel

Vicagrel: Vicagrel loading followed by Maintenance dose

Clopidogrel: Clopidogrel loading followed by Maintenance dose

Study summary

This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Patients between 18 and 80 years old, with no gender restrictions. * Patients diagnosed with ACS and scheduled for PCI, including STEMI and NSTE-ACS (UA/NSTEMI). * Voluntarily sign the ICF and be able to follow the visit arrangements specified in the protocol during the trial period. Exclusion Criteria: * Expected survival time\<12 months; * Severe liver dysfunction (non heart disease induced ALT or AST\>3x ULN) and cirrhosis; * Pregnant or lactating women, or participants and their partners who plan to become pregnant during the trial period; * The researchers determined that other reasons were not suitable for participants in this experiment.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
General Hospital of Northern Theater Command of Chinese PLA Shenyang Liaoning Recruiting

On this site

📄 Plavix (clopidogrel) drug profile →

More Jiangsu vcare pharmaceutical technology co., LTD trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06577519 on ClinicalTrials.gov ↗ ← All trials in China